Relative bioavailability of cardizem CD and tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers

American Journal of Therapeutics

Volumn 5, Issue 3, 1998, Pages 173-179

  Dimmitt, Dan C ^a   Bhargava, V O ^a   Arumugham, Thangam ^a   Eller, Mark ^a   Weir, Scott J ^a  

^a SANOFI   (France)

Author keywords

Bioavailability; Controlled release dosage form; Diltiazem; Pharmacokinetics

Indexed keywords

DEACETYLDILTIAZEM; DILTIAZEM; N NORDILTIAZEM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031832348     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199805000-00008     Document Type: Article

References (26)

1. Schwartz A, Grupp G, Millard RW, et al: Calciumchannel blockers: possible mechanism of protective effects on the ischemic myocardium. In: New Perspectives on Calcium Antagonists. (Ed. Weiss GB), American Physiological Society. Bethesda, MD, 1981, pp 191-210.
2. Frishman WH: Current status of calcium channel blockers. Curr Probl Cardiol 1994;19:637-688.
3. Smith MS, Verghese CP, Shand DG, et al: Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol 1983;51:1369-1374.
4. Ochs HR, Knuchel M: Pharmacokinetics and absolute bioavailability of diltiazem in humans. Klin Wochenschr 1984;62:303-306.
5. Morselli PL, Rovei V, Mitchard M, et al: Pharmacokinetics and metabolism of diltiazem in man (observations on healthy volunteers and angina pectoris patients). In: New Drug Therapy with a Calcium Antagonist: Diltiazem Hakone Symposium '78. (Ed. Bing RJ), Excerpta Medica, Amsterdam, The Netherlands, 1979, pp 152-167.
6. Blackwell B: Drug therapy: patient compliance. N Engl J Med 1973;289:249-252.
7. Eraker SA, Kirscht JP, Becker MH: Understanding and improving patient compliance. Ann Intern Med 1984; 100:258-268.
8. Eisen SA, Miller DK, Woodward RS, et al: The effect of prescribed daily dose frequency on patients' medication compliance. Arch Intern Med 1990;150:1881-1884.
9. Brun J: Patient compliance with once-daily and twicedaily oral formulations of 5-isosorbide mononitrate: a comparative study. J Intern Med Res 1994;22:266-272.
10. Frishman WH: A new extended-release formulation of diltiazem HCI for the treatment of mild-to-moderate hypertension. J Clin Pharmacol 1993;33:612-622.
11. Massie BM, Der E, Herman TS, et al: 24-hour efficacy of once-daily diltiazem in essential hypertension. Clin Cardiol 1992;15:365-368.
12. Cutler NR, Eff J, Fromell G, et al: Dose-ranging study of a new, once-daily diltiazem formulation for patients with stable angina. J Clin Pharmacol 1995;35:189-195.
13. Ziemniak J, Colligan I, Heald D: Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects. Clin Ther 1992;14:158-165.
14. Rovei V, Gomeni R, Mitchard M, et al: Pharmacokinetics and metabolism of diltiazem in man. Acta Cardiol 1980; 35:35-45.
15. Sugihara J, Sugawara Y, Ando H, et al: Studies on the metabolism of diltiazem in man. J Pharmacobio-Dyn 1984;7:24-32.
16. Lippert C, Arumugham T, Bhargava VO, et al: The relative bioavailability of two marketed controlled release diltiazem dosage forms at steady state in healthy volunteers. Biopharm Drug Dispos 1996;17:43-53.
17. Argenti D, Huang M-Y, Heald D, et al: Comparative pharmacokinetics and bioavailability of Dilacor XR and Cardizem CD in healthy volunteers. Am J Ther 1995;2: 20-30.
18. Weiner DA: Calcium channel blockers. Med Clin North Am 1988;72:83-115.
19. Biacnchetti G, Regazzi M, Rondanelli R, et al: Bioavailability of diltiazem as a function of the administered dose. Biopharm Drug Dispos 1991;12:391-401.
20. Cohn JN, Parmley W, Weart CW: The proper use of calcium channel blockers. Patient Care 1996;30:14-46.
21. Guidance: oral extended (controlled) release dosage forms. In vivo bioequivalence and in vitro dissolution testing. Office of Generic Drugs, Food and Drug Administration, Washington, DC, September 1993.
22. Castenada-Hernandez G, Caille G, du Souich P: Influence of drug formulations on drug concentration-effect relationships. Clin Pharmacokinet 1994;26:135-143.
23. Graefe KH, Ziegler R, Wingender W, et al: Plasma concentration-response relationship for some cardiovascular effects of dihydropyridines in healthy volunteers. Clin Pharmacol Ther 1988;43:16-22.
24. Kleinbloesem CH, van Brummelen P, Breimer DD: Nifedipine: relationship between pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1987;12:12-29.
25. Van Harten J, van Brummelen P, Zeegers RRECM, et al: The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. Br J Clin Pharmacol 1988;25:709-717.
26. Abernethy DR: Problematic factors in pharmacodynamic studies. In: Pharmacokinetics and Pharmacodynamics: Current Problems and Potential Solutions. (Ed. Kroboth P), Harvey Whitney Books, Cincinnati, OH, 1988, pp 60-74.